Increased Testosterone and Proinflammatory Cytokines in Patients with Polycystic Ovary Syndrome Correlate with Elevated GnRH Receptor Autoantibody Activity Assessed by a Fluorescence Resonance Energy Transfer-based Bioassay
Overview
Authors
Affiliations
Purpose: The recently identified agonistic autoantibodies (AAb) to the gonadotropin-releasing hormone receptor (GnRHR) are a novel investigative and therapeutic target for polycystic ovary syndrome (PCOS). In this study, we used a new cell-based fluorescence resonance energy transfer (FRET) bioassay to analyze serum GnRHR-AAb activity and examine its relationship with testosterone and proinflammatory cytokines in patients with PCOS.
Methods: Serum samples from 33 PCOS patients, 39 non-PCOS ovulatory infertile controls and 30 normal controls were tested for GnRHR-AAb activity and proinflammatory cytokines in a FRET-based bioassay and multiplex bead-based immunoassay, respectively. Correlation was analyzed using the Spearman's correlation test.
Results: Serum GnRHR-AAb activity was significantly higher in the PCOS patients than for the ovulatory infertile (p < 0.05) and normal (p < 0.01) controls. GnRHR-AAb were positive in 39% of PCOS patients, 10% of ovulatory infertile controls, and 0% of normal controls. PCOS IgG-induced GnRHR activation was specifically blocked by the GnRHR antagonist cetrorelix. Serum levels of proinflammatory cytokines interleukin-2, interleukin-6, interferon-γ, and tumor necrosis factor-α were significantly increased in PCOS patients compared with ovulatory infertile and normal controls (p < 0.01). Correlation analysis demonstrated positive correlations of GnRHR-AAb activity with testosterone and proinflammatory cytokine levels in the PCOS group.
Conclusions: Elevated GnRHR-AAb activity, as assessed by a new FRET assay, is associated with increased testosterone and proinflammatory cytokines in PCOS, suggesting autoimmune activation of GnRHR may contribute to the pathogenesis of this common disorder.
Mohammed N, Sulaiman G, Alabassi H, Khalil K, Ahmed E J Genet Eng Biotechnol. 2025; 23(1):100462.
PMID: 40074436 PMC: 11836498. DOI: 10.1016/j.jgeb.2025.100462.
Scarfo G, Daniele S, Fusi J, Gesi M, Martini C, Franzoni F Biomedicines. 2022; 10(6).
PMID: 35740328 PMC: 9219791. DOI: 10.3390/biomedicines10061305.
Liu Y, Li Z, Wang Y, Cai Q, Liu H, Xu C Front Endocrinol (Lausanne). 2022; 13:787876.
PMID: 35250857 PMC: 8894602. DOI: 10.3389/fendo.2022.787876.
Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium.
Xue Z, Li J, Feng J, Han H, Zhao J, Zhang J Front Physiol. 2022; 12:788772.
PMID: 34975540 PMC: 8718643. DOI: 10.3389/fphys.2021.788772.
Li H, Guo Y, Deng J, Gali H, Weedin E, Burks H Endocrine. 2021; 75(3):959-963.
PMID: 34807394 PMC: 8891032. DOI: 10.1007/s12020-021-02944-2.